Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13849934 | 1.00 | SLC1A1 (0.45) | SLC1A1PPARGPPARATAAR1PTGER4 | |
| SCHEMBL14402470 | 1.00 | SLC1A1 (0.45) | SLC1A1PPARGPPARATAAR1PTGER4 | |
| SCHEMBL14402789 | 0.90 | SLC1A1 (0.43) | SLC1A1PPARGPPARATAAR1PTGER4 | |
| SCHEMBL15178111 | 0.87 | SLC1A1 (0.49) | SLC1A1PPARGPPARATAAR1IDO1 | |
| SCHEMBL10586409 | 0.87 | SLC1A1 (0.49) | SLC1A1PPARGPPARATAAR1IDO1 | |
| SCHEMBL15178087 | 0.83 | CETP (0.34) | SLC1A1TAAR1 | |
| SCHEMBL15178072 | 0.83 | CETP (0.34) | SLC1A1TAAR1 | |
| SCHEMBL14402524 | 0.83 | HTR2A (0.33) | TAAR1 | |
| SCHEMBL14402448 | 0.83 | HTR2A (0.33) | TAAR1 | |
| SCHEMBL25482996 | 0.82 | TAAR1 (0.44) | SLC1A1PPARGPPARATAAR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767310-B2 | Nicotinamide RIPK1 inhibitors | ABBVIE INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230127127-A1 | NICOTINAMIDE RIPK1 INHIBITORS | ABBVIE INC. | 2023-04-27 | — | — | US | disclosed |
| EP-1847533-B1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-7531533-B2 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1847533-A1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127127-A1 | NICOTINAMIDE RIPK1 INHIBITORS | RIPK1, RIPK2, RIPK4 | SLC1A1 3811/4885PPARG 2412/4885PPARA 2653/4885 |
| US-11767310-B2 | Nicotinamide RIPK1 inhibitors | RIPK1, RIPK2, RIPK4 | SLC1A1 3811/4885PPARG 2412/4885PPARA 2653/4885 |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | WNT1, CYP11B2, CYP11B1 | SLC1A1 4301/4885PPARG 390/4885PPARA 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.